D-dimer Assay for Exclusion of Pulmonary Embolism First to Meet Advanced Standards
By LabMedica International staff writers Posted on 01 Oct 2014 |
For the first time a D-dimer assay for exclusion of pulmonary embolism (PE) meets the US Food and Drug Administration (FDA)’s approval requirements now based on the new and more restrictive standards established by the Clinical Laboratory Standards Institute (CLSI, H59-A).
Diagnostica Stago, Inc. (Parsippany, NJ, USA), the US subsidiary of Diagnostica Stago, S.A.S. (Asnières sur Seine, France), a leader in development and manufacture of hemostasis products for clinical research and routine analysis, received the FDA clearance for the reagent “STA-Liatest D-Di” for the exclusion of PE in patients with low or moderate risk, presenting at an emergency unit. Stago’s rapid, automated, and highly sensitive D-dimer assay is the first to comply with the higher standards.
In order to comply with the new CLSI guidelines, Stago performed a 2-year, international, prospective study, similar to clinical studies performed in the pharmaceutical field—9 sites, 5 countries, more than 1,100 patients, including evaluation of clinical pretest probability, imaging, and 3 months of follow-up—a first in the field of hemostasis diagnostics. As its coordinator, Prof. Gilles Pernod of Grenoble University Hospital (France) pointed out: “As well as providing the results required to validate this test for the exclusion of PE, this study brought to light a significant evolution of clinical practices and shifts in prevalence. In fact, these results will be presented in some interesting upcoming publications.”
This study also confirmed the excellent diagnostic performance of the STA-Liatest D-Di assay, with a very high negative predictive value (NPV) for the exclusion of PE, far exceeding FDA requirements (>99.7% versus 97%), and excellent sensitivity (>97% versus 95%). “STA-Liatest D-Di is the first D-Di assay to report comprehensive study data that focuses on US-specific care patterns in the package insert. Increases in FDA stringency raises the bar for demonstration of clinical utility and patient safety. Stago is proud for STA-Liatest D-Di to lead the way once again and set the standard for D-dimer assays,” said Stephane Zamia, PhD, CEO of Diagnostica Stago, Inc.
The second part of this international clinical study, concerning deep vein thrombosis (DVT), is underway and is due to be completed in the next few months, with the hope that it will provide the clinical science community with as much relevant data as the first.
Related Links:
Diagnostica Stago (US)
Diagnostica Stago
Diagnostica Stago, Inc. (Parsippany, NJ, USA), the US subsidiary of Diagnostica Stago, S.A.S. (Asnières sur Seine, France), a leader in development and manufacture of hemostasis products for clinical research and routine analysis, received the FDA clearance for the reagent “STA-Liatest D-Di” for the exclusion of PE in patients with low or moderate risk, presenting at an emergency unit. Stago’s rapid, automated, and highly sensitive D-dimer assay is the first to comply with the higher standards.
In order to comply with the new CLSI guidelines, Stago performed a 2-year, international, prospective study, similar to clinical studies performed in the pharmaceutical field—9 sites, 5 countries, more than 1,100 patients, including evaluation of clinical pretest probability, imaging, and 3 months of follow-up—a first in the field of hemostasis diagnostics. As its coordinator, Prof. Gilles Pernod of Grenoble University Hospital (France) pointed out: “As well as providing the results required to validate this test for the exclusion of PE, this study brought to light a significant evolution of clinical practices and shifts in prevalence. In fact, these results will be presented in some interesting upcoming publications.”
This study also confirmed the excellent diagnostic performance of the STA-Liatest D-Di assay, with a very high negative predictive value (NPV) for the exclusion of PE, far exceeding FDA requirements (>99.7% versus 97%), and excellent sensitivity (>97% versus 95%). “STA-Liatest D-Di is the first D-Di assay to report comprehensive study data that focuses on US-specific care patterns in the package insert. Increases in FDA stringency raises the bar for demonstration of clinical utility and patient safety. Stago is proud for STA-Liatest D-Di to lead the way once again and set the standard for D-dimer assays,” said Stephane Zamia, PhD, CEO of Diagnostica Stago, Inc.
The second part of this international clinical study, concerning deep vein thrombosis (DVT), is underway and is due to be completed in the next few months, with the hope that it will provide the clinical science community with as much relevant data as the first.
Related Links:
Diagnostica Stago (US)
Diagnostica Stago
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms